{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:51:14Z","timestamp":1761580274694},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T00:00:00Z","timestamp":1233619200000},"content-version":"vor","delay-in-days":4173,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[1997,9]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>In segments of human right atrial appendages and pulmonary arteries preincubated with [<jats:sup>3<\/jats:sup>H]\u2010noradrenaline and superfused with physiological salt solution containing desipramine and corticosterone, the involvement of imidazoline receptors in the modulation of [<jats:sup>3<\/jats:sup>H]\u2010noradrenaline release was investigated.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In human atrial appendages, the guanidines aganodine and DTG (1,3\u2010di(2\u2010tolyl)guanidine) which activate presynaptic imidazoline receptors, inhibited electrically\u2010evoked [<jats:sup>3<\/jats:sup>H]\u2010noradrenaline release. The inhibition was not affected by blockade of \u03b1<jats:sub>2<\/jats:sub>\u2010adrenoceptors with 1\u2003\u03bc<jats:sc>M<\/jats:sc> rauwolscine, but antagonized by extremely high concentrations of this drug (10 and\/or 30\u2003\u03bc<jats:sc>M<\/jats:sc>; apparent pA<jats:sub>2<\/jats:sub> against aganodine and DTG: 5.55 and 5.21, respectively).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In the presence of 1\u2003\u03bc<jats:sc>M<\/jats:sc> rauwolscine, [<jats:sup>3<\/jats:sup>H]\u2010noradrenaline release in human atrial appendages was also inhibited by the imidazolines idazoxan and cirazoline, but not by agmatine and noradrenaline. The inhibitory effects of 100\u2003\u03bc<jats:sc>M<\/jats:sc> idazoxan and 30\u2003\u03bc<jats:sc>M<\/jats:sc> cirazoline were abolished by 30\u2003\u03bc<jats:sc>M<\/jats:sc> rauwolscine.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In the atrial appendages, the rank order of potency of all guanidines and imidazolines for their inhibitory effect on electrically\u2010evoked [<jats:sup>3<\/jats:sup>H]\u2010noradrenaline release in the presence of 1\u2003\u03bc<jats:sc>M<\/jats:sc> rauwolscine was: aganodineBDF\u20036143 [4\u2010chloro\u20102\u2010(2\u2010imidazolin\u20102\u2010yl\u2010amino)\u2010isoindoline]&gt;DTGclonidine&gt;cirazoline&gt;idazoxan (BDF\u20036143 and clonidine were previously studied under identical conditions). This potency order corresponded to that previously determined at the presynaptic imidazoline receptors in the rabbit aorta.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>When, in the experiments in the human pulmonary artery, rauwolscine was absent from the superfusion fluid, the concentration\u2010response curve for BDF\u20036143 (a mixed \u03b1<jats:sub>2<\/jats:sub>\u2010adrenoceptor antagonist\/imidazoline receptor agonist) for its facilitatory effect on electrically\u2010evoked [<jats:sup>3<\/jats:sup>H]\u2010noradrenaline release was bell\u2010shaped. In the presence of 1\u2003\u03bc<jats:sc>M<\/jats:sc> rauwolscine, BDF\u20036143 and cirazoline concentration\u2010dependently inhibited the evoked [<jats:sup>3<\/jats:sup>H]\u2010noradrenaline release.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In human atrial appendages, non\u2010adrenoceptor [<jats:sup>3<\/jats:sup>H]\u2010idazoxan binding sites were identified and characterized. The binding of [<jats:sup>3<\/jats:sup>H]\u2010idazoxan was specific, reversible, saturable and of high affinity (<jats:italic>K<\/jats:italic><jats:sub>D<\/jats:sub>: 25.5\u2003n<jats:sc>M<\/jats:sc>). The specific binding of [<jats:sup>3<\/jats:sup>H]\u2010idazoxan (defined by cirazoline 0.1\u2003m<jats:sc>M<\/jats:sc>) to membranes of human atrial appendages was concentration\u2010dependently inhibited by several imidazolines and guanidines, but not by rauwolscine and agmatine. In most cases, the competition curves were best fitted to a two\u2010site model.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The rank order of affinity for the high affinity site (in a few cases for the only detectable site; cirazoline=idazoxan&gt;BDF\u20036143&gt;DTGclonidine) is compatible with the pharmacological properties of I<jats:sub>2<\/jats:sub>\u2010imidazoline binding sites, but is clearly different from the rank order of potency for inhibiting evoked noradrenaline release from sympathetic nerves in the same tissue.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>It is concluded that noradrenaline release in the human atrium and, less well established, in the pulmonary artery is inhibited via presynaptic imidazoline receptors. These presynaptic imidazoline receptors appear to be related to those previously characterized in rabbit aorta and pulmonary artery, but differ clearly from I<jats:sub>1<\/jats:sub> and I<jats:sub>2<\/jats:sub> imidazoline binding sites.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (1997) <jats:bold>122<\/jats:bold>, 43\u201350; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0701343\">10.1038\/sj.bjp.0701343<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0701343","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T19:14:01Z","timestamp":1106939641000},"page":"43-50","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Presynaptic imidazoline receptors and non\u2010adrenoceptor[<sup>3<\/sup>H]\u2010idazoxan binding sites in human cardiovascular tissues"],"prefix":"10.1111","volume":"122","author":[{"given":"G. J.","family":"Molderings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Likungu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jakschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"G\u00f6thert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,3]]},"reference":[{"key":"e_1_2_3_2_1","first-page":"121","article-title":"International union of pharmacology nomenclature of adrenoceptors","volume":"46","author":"Bylund D. B.","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(87)90125-7"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199220004-00002"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00171336"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00164788"},{"key":"e_1_2_3_8_1","first-page":"235","volume-title":"Handbook of Experimental Pharmacology. Catecholamines","author":"Furchgott R. F.","year":"1972"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00251126"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7906055"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00170847"},{"key":"e_1_2_3_12_1","first-page":"324","article-title":"[3H]\u2010Idazoxan and some other \u03b12\u2010adrenergic drugs also bind with high affinity to a nonadrenergic sites","volume":"35","author":"Michel M. C.","year":"1989","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00168628"},{"key":"e_1_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00171042"},{"key":"e_1_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174746"},{"key":"e_1_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00175030"},{"issue":"1","key":"e_1_2_3_17_1","first-page":"R9","article-title":"Presynaptic imidazoline receptors and [3H]idazoxan binding sites in human right atrium","volume":"354","author":"Molderings G. J.","year":"1996","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"e_1_2_3_18_1","unstructured":"Molderings G. J. Likungu J.&G\u00f6thert M.(1997).Characterization of presynaptic imidazoline receptors and [3H]idazoxan binding sites in human right atrium.J. Autonom. Pharmacol. (in press)."},{"key":"e_1_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00168539"},{"key":"e_1_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(96)81564-1"},{"key":"e_1_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.36.040196.002455"},{"key":"e_1_2_3_22_1","first-page":"29","article-title":"Receptor interactions of Imidazolines. IX. Cirazoline is an alpha\u20101 adrenergic agonist and an alpha\u20102 adrenergic antagonist","volume":"22","author":"Ruffolo R. R.","year":"1982","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb17216.x"},{"key":"e_1_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199509000-00017"},{"key":"e_1_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BFb0034538"},{"key":"e_1_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/BFb0027645"},{"key":"e_1_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.22.8784"},{"key":"e_1_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1992.tb00459.x"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0701343","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0701343","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0701343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T06:28:40Z","timestamp":1718864920000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0701343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,9]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,9]]}},"alternative-id":["10.1038\/sj.bjp.0701343"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0701343","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,9]]},"assertion":[{"value":"2009-02-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}